본문 바로가기

Efficacy and Safety of Bojungikgi-Tang for Persistent Allergic Rhinitis: A Study Protocol for a Randomized, Double-Blind, Placebo-Controlled, Phase II Trial

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q3Scopus Q2
피인용
Web of Science 1Scopus 1
FWCI (Scopus)
0.15
JCR IF
JCR 2021 2.65
ISSN
1741-427X

저자

  1. Lee, Su Won제1저자Daejeon Univ, Coll Korean Med, Dept Internal Med, Div Resp Med, Daejeon, South Korea
  2. Choi, Jin KwanDaejeon Univ, Coll Korean Med, Dept Internal Med, Div Resp Med, Daejeon, South Korea
  3. Lyu, Yee RanDaejeon Univ, Coll Korean Med, Dept Internal Med, Div Resp Med, Daejeon, South Korea
  4. Yang, Won KyungDaejeon Univ, Coll Korean Med, Dept Internal Med, Div Resp Med, Daejeon, South Korea
  5. Kim, Seung HyungDaejeon Univ, Inst Tradit Med & Biosci, Daejeon, South Korea
  6. Kim, Je HyunDaejeon Univ, Daejeon Korean Med Hosp, Clin Trial Ctr, Daejeon, South Korea
  7. Kim, Si YeonDaejeon Univ, Daejeon Korean Med Hosp, Clin Trial Ctr, Daejeon, South Korea
  8. Kang, WeechangDaejeon Univ, Grad Sch, Dept Stat, Daejeon, South Korea
  9. Jung, In ChulDaejeon Univ, Daejeon Korean Med Hosp, Clin Trial Ctr, Daejeon, South Korea
  10. Lee, Beom JoonKyung Hee Univ, Coll Oriental Med, Dept Internal Med, Div Allergy Immune & Resp Syst, Seoul, South Korea
  11. 최준용Pusan Natl Univ, Sch Korean Med, Dept Internal Med, Busan, South Korea
  12. Kim, Taesoo교신저자Korea Inst Oriental Med, Daejeon, South Korea
  13. Park, Yang Chun교신저자Daejeon Univ, Coll Korean Med, Dept Internal Med, Div Resp Med, Daejeon, South Korea

초록

Background. Allergic rhinitis (AR) is a common disease, and conventional medications are often insufficient for treatment. Bojungikgi-tang (BJIGT) is an herbal medicine widely used in traditional medicine and has anti-inflammatory and immunoregulatory effects. We hypothesize that BJIGT would improve nasal symptoms in patients with persistent AR (PAR). Methods. This is a randomized, double-blind, placebo-controlled, phase II trial. A total of 105 patients, identified with perennial allergens, with a history of PAR and a mean total nasal symptom score (TNSS)>= 5 during the run-in period will be recruited from Daejeon Korean Medicine Hospital. Participants will be randomly assigned to a high-dose BJIGT group, standard-dose BJIGT group, or control group (placebo) in a 1:1:1 allocation ratio after a week run-in period. The treatment medication will be taken three times per day for 4 weeks. The primary outcome measure is the mean change in the TNSS before and after medication. The secondary outcome measures include the Korean Allergic Rhinitis-Specific Quality of Life Questionnaire, total IgE and eosinophil count, overall assessment of AR, pattern identification questionnaire for AR, and Sasang constitution. Discussion. The aim of this study is to investigate the efficacy and safety of BJIGT in the treatment of PAR and to determine the suitable dosage of BJIGT. Therefore, we planned a randomized, controlled, phase II trial of two different doses of BJIGT compared with placebo, and the results of this study are expected to provide evidence for the use of BJIGT as a treatment of PAR. Trial Registration. The National Clinical Trial Registry Clinical Research Information Service, CRIS, KCT0006616, https://cris.nih.go.kr/cris/search/detailSearch.do/20706.

키워드

HOCHU-EKKI-TOGUIDELINEMEDICINEIMPACT

식별자

Scopus EID
2-s2.0-85145800339
WoS UID
000838699800002